Mendus

IMMU · Nasdaq Stockholm

Public Market Listing

IMMUNasdaq Stockholm

Nasdaq Stockholm primary exchange listing

Live quotes, historical charts, and market capitalization for Mendus are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2
Allogeneic dendritic cell vaccineVaccine
Acute Myeloid LeukemiaChronic Myeloid Leukemia

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (9)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q4$0-$3.7M$7.0M$4.4Mreport ↗
View 8 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q3$0-$1.4M$4.0M$2.0Mreport ↗
2025-Q2$0—$6.2M$2.4Mreport ↗
2025-Q1$0—$8.4M$2.9Mreport ↗
2024-Q4$0-$2.5M$9.3M$2.9Mreport ↗
2024-Q3$0-$1.6M$11M$2.2Mreport ↗
2024-Q2$0—$12M$3.6Mreport ↗
2024-Q1$0—$8.3M$3.4Mreport ↗
2023-Q4$0—$12M$3.9Mreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0-$8.7M$7.0M—report ↗

Mendus reported revenue of $0M, R&D spend of $-8.69M, down 247.6% YoY, cash and equivalents of $7.03M, and a net loss of $11.57M for fiscal year 2025.

Figures only: this period's report disclosed no narrative text

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0-$9.6M$9.3M—report ↗
2023-FY$0-$8.7M$12M—report ↗
2022-FY$0—$4.0M—report ↗
2021-FY$0—$17M—report ↗